Skip to main content
. Author manuscript; available in PMC: 2020 Mar 28.
Published in final edited form as: Vaccine. 2019 Mar 4;37(14):2026–2033. doi: 10.1016/j.vaccine.2019.01.002

Table 3.

Cost-effectiveness Analysis Results*

Assuming PPSV23 is NOT effective vs. non-bacteremic pneumonia Incremental Cost- Effectiveness
Black Population
Present recommendations (high-risk get PPSV23, immunocompromised get PCV13/PPSV23) $37,346
All get PPSV23 $123,087
All get PCV13/PPSV23 $284,654
General Population
Present recommendations $42,068
High-risk, immunocompromised get PCV13/PPSV23 $220,251
All get PCV13/PPSV23 $258,573
Assuming PPSV23 IS effective vs. non-bacteremic pneumonia
Black Population
High-risk, immunocompromised get PPSV23 $14,786
Present recommendations $15,357
All get PPSV23 $43,957
All get PCV13/PPSV23 $752,245
General Population
High-risk, immunocompromised get PPSV23 $14,556
Present recommendations $24,497
All get PPSV23 $81,002
All get PCV13/PPSV23 $522,774
*

Dominated strategies not shown